Natalia Marina Cardillo

Dr. Natalia Marina Cardillo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
NCNatalia Marina Cardillo
Natalia Marina Cardillo
PLPaul A. Lacy
Paul A. Lacy
NVNicolas F. Villarino
Nicolas F. Villarino
JDJ. Stone Doggett
J. Stone Doggett
MRMichael K. Riscoe
Michael K. Riscoe
Carlos E. SuárezCarlos E. Suárez
Carlos E. Suárez
Introduction: B. bovis is an apicomplexan parasite responsible for bovine babesiosis, a tick-borne disease with a worldwide impact. The disease remains inefficiently controlled, and few effective drugs, including imidocarb dipropionate (ID), are currently available in endemic areas. The objective of this study was to evaluate whether buparvaquone (BPQ), a drug currently used to treat cattle infected with the Babesia-related Theileria spp. parasites, could be active against Babesia parasites. Herein, we compared the effect of ID and BPQ on B. bovis growth in vitro erythrocyte culture.Methods: We compared the effect of ID and BPQ on the culture-adapted Texas T2Bo strain of B. bovis. In vitro cultured parasites were incubated with ID and BPQ at two starting parasitemia levels (PPE), 0.2% and 1%. In vitro cultured parasites were treated with ID or BPQ at concentrations ranging from 10 to 300 nM, during 4 consecutive days. Parasitemia levels were daily evaluated using microscopic examination. Data was compared using the independent Student’s t-test.Results and discussion: Both ID and BPQ significantly inhibited (p < 0.05) the growth of B. bovis, regardless of the initial parasitemia used. At 1% parasitemia, BPQ had lower calculated inhibitory concentration 50 (IC50: 50.01) values than ID (IC50: 117.3). No parasites were found in wells with 0.2% starting parasitemia, treated previously with 50 nM of BPQ or ID, after 2 days of culture without drugs. At 1% parasitemia, no parasite survival was detected at 150 nM of BPQ or 300 nM of ID, suggesting that both drugs acted as babesiacidals.Conclusion: Overall, the data suggests that BPQ is effective against B. bovis and shows a residual effect that seems superior to ID, which is currently the first-line drug for treating bovine babesiosis globally.

31 October 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NCNatalia Marina Cardillo
Natalia Marina Cardillo
NVNicolas F. Villarino
Nicolas F. Villarino
PLPaul A. Lacy
Paul A. Lacy
MRMike Riscoe
Mike Riscoe
JDJoseph Stone Doggett
Joseph Stone Doggett
Carlos E. SuárezCarlos E. Suárez
Carlos E. Suárez
Background/Objectives: Bovine babesiosis is a vector-borne disease transmitted by ticks that causes important losses in livestock worldwide. Recent research performed on the drugs currently used to control bovine babesiosis reported several issues including drug resistance, toxicity impact, and residues in edible tissue, suggesting the need for developing novel effective therapies. The endochin-like quinolones ELQ-316 and buparvaquone (BPQ) act as cytochrome bc1 inhibitors and have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp. and Babesia microti, without showing toxicity in mammals. The objectives of this study are investigating whether ELQ-316, BPQ, and their combination treatment could be effective against Babesia bovis in an in vitro culture model and comparing with imidocarb (ID), the routinely used drug. Methods: In vitro cultured parasites starting at 2% percentage of parasitemia (PPE) were treated with BPQ, ELQ-316, ID, and the combinations of BPQ + ELQ-316 and ID + ELQ-316 at drug concentrations that ranged from 25 to 1200 nM, during four consecutive days. The IC50% and IC99% were reported. Parasitemia levels were evaluated daily using microscopic examination. Data were compared using the non-parametrical Mann–Whitney and Kruskall–Wallis test. Results: All drugs tested, whether used alone or in combination, significantly decreased the survival (p < 0.05) of B. bovis in in vitro cultures. The combination of BPQ + ELQ-316 had the lowest calculated inhibitory concentration 50% (IC50%) values, 31.21 nM (IC95%: 15.06–68.48); followed by BPQ, 77.06 nM (IC95%: 70.16–86.01); ID + ELQ316, 197 nM (IC95%:129.0–311.2); ID, 635.1 nM (IC95%: 280.9–2119); and ELQ316, 654.9 nM (IC95%: 362.3–1411). Conclusions: The results reinforce the higher efficacy of BPQ at affecting B. bovis survival and the potential synergistic effects of its combination with ELQ-316, providing a promising treatment option against B. bovis.

6 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NCNatalia Marina Cardillo
Natalia Marina Cardillo
NVNicolas F. Villarino
Nicolas F. Villarino
PLPaul A. Lacy
Paul A. Lacy
JDJoseph S. Doggett
Joseph S. Doggett
MRMike Riscoe
Mike Riscoe
CCChung J. Chungwon
Chung J. Chungwon
Background/Objectives: B. bigemina is a highly pathogenic and widely distributed tick-borne disease parasite responsible for bovine babesiosis. The development of effective and safe therapies is urgently needed for global disease control. The aim of this study is to compare the effects of endochin-like quinolone (ELQ-316), buparvaquone (BPQ), imidocarb (ID), and the combinations of ID + ELQ-316 and BPQ + ELQ-316, on in vitro survival of B. bigemina. Methods: Parasites at a starting parasitemia level of 2%, were incubated with each single drug and a combination of drugs, ranging from 25 to 1200 nM of concentration over four consecutive days. The inhibitory concentrations, 50% (IC50%) and 99% (IC99%), were estimated. Parasitemia levels were evaluated daily using microscopic examination. Data were statistically compared using the non-parametrical Kruskall–Wallis test. Results: All drugs tested significantly inhibited (p < 0.05) the growth of B. bigemina at 2% parasitemia. The combination of ID + ELQ-316 exhibited a lower mean (IC50%: 9.2; confidence interval 95%: 8.7–9.9) than ID (IC50%: 61.5; confidence interval 95%: 59.54–63.46), ELQ-316 (IC50%: 48.10; confidence interval 95%: 42.76–58.83), BPQ (IC50%: 44.66; confidence interval 95%: 43.56–45.81), and BPQ + ELQ-316 (IC50%: 27.59; confidence interval: N/A). Parasites were no longer viable in cultures treated with the BPQ + ELQ-316 combination, as well as with BPQ alone at a concentration of 1200 nM, on days 2 and 3 of treatment, respectively. Conclusions: BPQ and ID increase the babesiacidal effect of ELQ-316. The efficacy of these combinations deserves to be evaluated in vivo, which could lead to a promising and safer treatment option for B. bigemina.

27 January 2026 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
NCNatalia Marina Cardillo
Natalia Marina Cardillo
NVNicolas F. Villarino
Nicolas F. Villarino
LKLowell Kappmeyer
Lowell Kappmeyer
CCChung J. Chungwon
Chung J. Chungwon
Carlos E. SuárezCarlos E. Suárez
Carlos E. Suárez
Reginaldo BastosReginaldo Bastos
Reginaldo Bastos
Background: Equine piroplasmosis (EP) is a tick-borne disease of equids caused by the intraerythrocytic apicomplexan parasites Theileria equi , Babesia caballi and the recently identified Theileria haneyi . Acute cases can be severe, with anemia, jaundice, abortion or sudden death. Survivors remain lifelong carriers, serving as reservoirs for tick-borne and iatrogenic transmission. No vaccines are currently available, and control strategies rely heavily on accurate diagnostics and chemotherapeutic intervention. Imidocarb dipropionate (ID) is the current standard of care for both acute treatment and radical cure. However, growing concerns regarding ID-resistant parasite strains and its associated toxicity have highlighted the urgent need for novel, safer and more effective antiparasitic agents. Here, we assessed the in vitro efficacy of tafenoquine succinate (TFQ), a synthetic 8-aminoquinoline with broad antiparasitic activity, against T. equi and B. caballi as a potential treatment for equine piroplasmosis. Methods: The effect of TFQ on T. equi and B. caballi was evaluated in vitro in parasite cultures. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of TFQ on parasite growth was compared to that of ID. TFQ toxicity on horse peripheral blood mononuclear cells (PBMCs) was assessed via a colorimetric metabolic assay. Results: TFQ reduced T. equi parasitemia in a dose-dependent manner, matching ID efficacy at 72 h. For B. caballi , TFQ had no effect at 5–10 µM but inhibited growth at 15 µM, similar to the results obtained with ID. TFQ exhibited approximately threefold greater potency against T. equi [half-maximal inhibitory concentration [IC 50 ] 5.90 μM, 95% confidence interval (CI) 4.99–5.96; 99% inhibitory concentration (IC 99 ) 60.74 μM, 95% CI 37.41–113.3] compared to B. caballi [IC 50 14.5 μM, 95% CI 13.81–15.23; IC 99 20.44 μM, 95% CI 17.77–28.84]. The narrower confidence intervals for T. equi suggest a more consistent antiparasitic response across replicates. Cytotoxicity assays showed no toxic effects on equine PBMCs at 2.5–5 μM ( P > 0.05), while concentrations ≥ 10 μM indicated potential toxicity. These findings suggest that TFQ selectively targets parasites over host cells, supporting its therapeutic potential. Conclusions: TFQ significantly inhibited T. equi and B. caballi growth at doses tolerated by equine PBMCs, supporting its potential as an alternative treatment for EP and warranting further in vivo study.

30 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NCNatalia Marina Cardillo
Natalia Marina Cardillo
NVNicolas F. Villarino
Nicolas F. Villarino
PLPaul A. Lacy
Paul A. Lacy
MRMike Riscoe
Mike Riscoe
JDJ. Stone Doggett
J. Stone Doggett
Carlos E. SuárezCarlos E. Suárez
Carlos E. Suárez
Background/Objectives: Bovine babesiosis is a vector-borne disease transmitted by ticks that causes important losses in livestock worldwide. Recent research performed on the drugs currently used to control bovine babesiosis reported several issues including drug resistance, toxicity impact, and residues in edible tissue, suggesting the need for developing novel effective therapies. The endochin-like quinolones ELQ-316 and buparvaquone (BPQ) act as cytochrome bc1 inhibitors and have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp. and Babesia microti, without showing toxicity in mammals. The objectives of this study are investigating whether ELQ-316, BPQ and their combination treatment could be effective against Babesia bovis in an in vitro culture model, and comparing with imidocarb (ID), the routinely used drug. Methods: In vitro cultured parasites at starting 2% percentage of parasitemia (PPE) were treated with BPQ, ELQ-316, ID, and the combinations of BPQ+ ELQ-316 and ID+ ELQ-316 at drug concentrations that ranged from 25 to 1200 nM, during four consecutive days. Parasitemia levels were evaluated daily using microscopic examination. Data was compared using the independent Student's t-test and ANOVA test. Results: All drugs tested, whether used alone or in combination, significantly decreased the survival (p<0.05) of B. bovis in in vitro cultures. The combination of BPQ+ ELQ-316 had the lowest calculated inhibitory concentration 50 (IC50) 31.21 nM (IC95%: 15.06 - 68.48) values, followed by BPQ, 77.06 nM (IC95%: 70.16- 86.01), ID+ELQ316 197 nM (IC95%:129.0 - 311.2), ID 635.1 nM (IC95%: 280.9 – 2119) and ELQ316 654.9 nM (IC95%: 362.3 – 1411). Conclusion: The results reinforce the higher efficacy of BPQ at affecting B. bovis survival, and the potential synergistic effects of its combination with ELQ-316, providing a promising treatment option against B. bovis.

20 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NCNatalia Marina Cardillo
Natalia Marina Cardillo
NVNicolas F. Villarino
Nicolas F. Villarino
PLPaul A. Lacy
Paul A. Lacy
JDJoseph S. Doggett
Joseph S. Doggett
MRMike Riscoe
Mike Riscoe
CCChung J. Chungwon
Chung J. Chungwon
Background/Objectives: B. bigemina is a highly pathogenic and widely distributed tick-borne disease parasite responsible for bovine babesiosis. The development of effective and safe therapies is urgently needed for global disease control. The aim of this study was to compare the effects of endochin-like quinolone (ELQ316), buparvaquone (BPQ), imidocarb (ID), and the combinations of ID + ELQ-316 and BPQ + ELQ-316, on in vitro survival of B. bigemina. Methods: Parasites at a starting parasitemia level of 2%, were incubated with each single drug and combination of drugs, ranging from 25 to 1200 nM of concentration over four consecutive days. The inhibitory concentration 50% (IC50%) and 99% (IC99%) were estimated. Parasitemia levels were evaluated daily using microscopic examination. Data were statistically compared using the non-parametrical KruskallWallis test. Results: All drugs tested significantly inhibited (p<0.05) the growth of B. bigemina at 2% parasitemia. The combination of ID + ELQ-316 exhibited lower mean IC50% (9.2); confidence interval 95% (8.7 – 9.9) than ID (IC50%: 61.5; confidence interval 95%: 59.54 - 63.46), ELQ-316 (IC50%: 48.10; confidence interval 95%: 42.76 – 58.83), BPQ (IC50%: 44.66; confidence interval 95%: 43.56 – 45.81), and BPQ + ELQ-316 (IC50%: 27.59; confidence interval: N/A). Parasites were no longer viable in cultures treated with the BPQ + ELQ-316 combination, as well as with BPQ alone at a concentration of 1200 nM, on days 2 and 3 of treatment, respectively.; Conclusions: BPQ and ID increase the babesiacidal effect of ELQ-316. The efficacy of these combinations deserves to be evaluated in vivo, which could lead to a promising and safer treatment option against B. bigemina.